ArrowMark Colorado Holdings LLC Purchases 113,603 Shares of Exact Sciences Corporation $EXAS

ArrowMark Colorado Holdings LLC boosted its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 23.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 597,931 shares of the medical research company’s stock after purchasing an additional 113,603 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 0.32% of Exact Sciences worth $32,713,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Comerica Bank grew its position in shares of Exact Sciences by 9.2% during the 3rd quarter. Comerica Bank now owns 1,954 shares of the medical research company’s stock worth $107,000 after buying an additional 164 shares in the last quarter. Great Lakes Advisors LLC raised its holdings in shares of Exact Sciences by 3.7% in the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 178 shares in the last quarter. Capital Asset Advisory Services LLC lifted its stake in Exact Sciences by 4.8% in the third quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company’s stock worth $216,000 after acquiring an additional 182 shares during the period. Assetmark Inc. lifted its stake in Exact Sciences by 7.2% in the third quarter. Assetmark Inc. now owns 3,588 shares of the medical research company’s stock worth $196,000 after acquiring an additional 242 shares during the period. Finally, Westside Investment Management Inc. grew its holdings in Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after acquiring an additional 271 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

Exact Sciences Stock Up 0.3%

NASDAQ:EXAS opened at $103.57 on Friday. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $103.75. The stock has a market capitalization of $19.77 billion, a P/E ratio of -94.15, a P/E/G ratio of 2.36 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The company’s 50-day simple moving average is $102.83 and its 200-day simple moving average is $83.86.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same quarter in the prior year, the business posted ($0.06) EPS. The business’s revenue was up 23.1% compared to the same quarter last year. On average, equities analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on EXAS. Stifel Nicolaus restated a “hold” rating and issued a $105.00 price target (up from $80.00) on shares of Exact Sciences in a report on Friday, November 28th. TD Cowen downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Canaccord Genuity Group lowered shares of Exact Sciences from a “buy” rating to a “hold” rating and lifted their price objective for the company from $85.00 to $105.00 in a report on Tuesday, November 25th. Guggenheim downgraded shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research note on Thursday, November 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Twenty-one equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $92.13.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.